Venclexta (ABT-199) is a selective small molecule Bcl-2 inhibitor being investigated for the treatment of multiple cancers.

Type of Molecule

Small Molecule

Target

Bcl-2

Region

US (Venclexta), EU (Venclyxto)

Potential Indication Product Type Phase (1, 2, 3, Submitted, Approved)
Chronic Lymphocytic Leukemia (CLL) with 17p deletion (US, EU) New Indication Phase Approved Approved
Chronic Lymphocytic Leukemia (CLL) - relapsed refractory and first line New Indication Phase 3
Multiple Myeloma (MM) New Indication Phase 3
Acute Myeloid Leukemia (AML) New Indication Phase 3
Follicular Lymphoma (FL) New Indication Phase 2
Diffuse Large B-Cell Lymphoma (DLBCL) New Indication Phase 2
Myelodysplatic Syndrome (MDS) New Indication Phase 2